Kas Gevşetici İlaç Cabral®(Feniramidol)’ın Mutajenik Etkisinin Ames Salmonella/Mikrozom Test Yöntemi İle Araştırılması

Year 2016, Volume: 6 Issue: 2, 67 - 73, 31.07.2016

Mehmet Arslan

https://doi.org/10.17714/gufbed.2016.06.008

Cited By: 1

Abstract

Günümüzde yaygın olarak kullanılan feniramidol (Cabral®) kas gevşetici etki gösteren analjezik bir ilaçtır. Bu çalışmada amaç feniramidol’ün potansiyel mutajenik etkisinin Ames Salmonella/Mikrozom test sistemi ile saptanmasıdır. Bu amaçla mutajenik etkiyi belirlemek için feniramidol’ün ticari formu olan Cabral®’ın 5 farklı dozu (0.1-1000 µg/plak) Salmonella typhimurium’un TA98 ve TA100 suşları ile muamele edilmiştir. Elde edilen bulgulara göre feniramidol’ün denenen hiçbir dozu TA98 ve TA100 suşlarında mutajenik etki göstermemiştir.

Keywords

Ames Salmonella/Mikrozom testi, Cabral®, Feniramidol, Mutajen

References

• Balbi, A., Muscettola, G., Staiano, N., Martire, G. ve De Lorenzo, F., 1980. Psychotropic drugs: evaluation of mutagenic effect, Pharmacological Research Communications, 12, 423-431.
• Black, H., Szot, R., Arthaud, L., Massa, T., Mylecraine, L., Klein, M., et al., 1987. Preclinical safety evaluation of the benzodiazepine quazepam, Arzneimittel-Forschung/Drug Research, 37, 8 906-913.
• Boyacıoğlu, M., Arslan, Ç.Ö., Parlak, H. ve Karaaslan, M., 2007. Mutagenicity of Nonylphenol and Octylphenol Using Salmonella Mutation Assay, E.U. Journal of Fisheries & Aquatic Sciences, 24, 3-4, 299–302.
• Bökesoy, T. A., Çakıcı, İ. ve Melli, M., 2000, Genel Farmakoloji ve Toksikoloji, Gazi Kitabevi, Ankara, 86-101s.
• Brambillaa, G., Carrozzinob, R. ve Martellia, A., 2007. Genotoxicity and carcinogenicity studies of benzodiazepines, Pharmacological Research, 56, 6, 443-458.
• Chlopkiewicz, B., Ejchart, A. ve Anuszewska, E., 2001. Tofisopam—evaluation of mutagenic and genotoxic properties, Acta Poloniae Pharmaceutica - Drug Research, 58, 31-34.
• Dean, B., Brooks, T., Hodson-Walker, G. ve Hutson, D., 1985. Genetic toxicology testing of 41 Industrial chemicals, Mutation Research, 153, 57-77.
• Debnath, A., Compadre, R., Debnath, G., Shusterman, A. ve Hansch, G., 1991. Strure-Activity Relationship of Mutagenic Aromatic and Heteroaromatic Nitro Compounds Correletion Molecular with Orbital Energies and Hydrophobicity, Journal of Medicinal Chemistry, 34, 2, 786-797.
• Ibrulj, S. ve Nefıc, H., 1999. Diazepem induced chromosome aberrations in human lymphocytes in vitro, Medicinski arhiv, 53, 1, 3-5.
• Igloe, M.C., 1963. The use of injectable phenyramidol in musculoskeletal disorders, Industrial Medicine & Surgery, 32, 242-247.
• Karahalil, B., Yağar, S., Bahadır, G., Durak, P. ve Sardaş, S., 2005. Diazepam and propofol used as anesthetics during open-heart surgery do not cause chromosomal aberrations in peripheral blood lymphocytes, Mutation Research, 581, 1-2, 181-186.
• Kayraldız, A.,, Kaya, F. F., Canımoglu, S. ve Rencüzoğulları, E., 2006. Mutagenicity of five food additives in Ames/Salmonella/Microsome test, Annals of Microbiology, 56, 2, 129-133.
• Kier, L., Brusick, D., Auletta, A., Halle, E.V., Brown, M., Simmon, V., et al., 1986. The Salmonella typhimurium/mammalian microsomal assay. A report of the U.S. Environmental Protection Agency Gene-Tox Program, Mutation Research, 168, 2, 69-240.
• Köksal, A., Köklü, S., Filik, L., Şaşmaz, N. ve Şahin, B., 2003. Phenyramidol– Associated Liver Toxicity, Annals of Pharmacotherapy, 37, 1244-1246.
• Koksal, P.M. ve Gürbüzel, M., 2015. Analysis of genotoxic activity of ketamine and rocuronium bromide using the somatic mutation and recombination test in Drosophila melanogaster, Environmental Toxicology and Pharmacology, 39(2): 628-634.
• Kutlu, M., Öztaş, E., Aydoğan, G., Işıkdağ, İ. ve Özkay, Y., 2011. Bazı 9-Sübstitüe Fenantren Türevlerinin Mutajenik Aktivitelerinin Ames/Salmonella/ Mikrozom Testi İle Araştırılması, Anadolu Üniversitesi Bilim ve Teknoloji Dergisi-Yaşam Bilimleri ve Biyoteknoloji, 1,1, 83-94.
• Leal, C.G., Valencıan, G., Rojas, M. ve Cortes, E.G., 1998. Mutagenic activity of diazepam evaluated by in vivo cytogenetic tests, Archives of Medical Research, 29, 4, 285-289.
• Maron, D. ve Ames, B., 1983. Revised methods for the Salmonella mutagenicity test, Mutation Research, 113, 173-215.
• Mortelmans K. ve Zeiger, E.E., 2000. The Ames Salmonella/microsome mutagenicity assay, Mutation Research, 455, 1-2, 29-60.
• O’Dell, T., Wilson, L., Napoli, M., White, H. ve Mirsky, J.H., 1960. Pharmacology of a series of new 2-substituted pyridine derivatives with emphasis on their analgesic and interneuronal blocking properties, The Journal of Pharmacology and Experimental Therapeutics, 28, 65-74.
• Staiano, M. N., Belisario, R., Morte, C.D., Farina, P. ve Rimondelli, G., 1984. Muscettola Mutagenic effects of flunitrazepam, Bollettino della Societa Italiana di Biologia Sperimentale, 60, 2247-2253.
• Stoyanov, I., Nikolov, I., Chernozemskii, I. ve Stoichev, I., 1987. Assessment for mutagenicity of 10 pharmaceutical products following Ames, micronucleus, and sperm morphology testing, Toxicity Assessment, 2, 2, 207-215.
• Synder, L. ve Champness, W., 2007. Third Edition Moleküler Genetics of Bacteria, Department of Microbiology and Moleculer Genetics, Michigon State University East Lansing, Michigan Washigton, DC, 492.
• Veronese, M. ve Barzaghi, D., 1987. Experimental studies in vitro and in vivo on the mutagenicity of flavoxate, Arzneimittel-Forschung, 37, 5, 528-531.
• Wakisaka, Y. ve Nishimoto, Y., 1987. Mutagenicity study on a new sleep inducer, a 1H-1,2,4-triazolylbenzophenone derivative (450191-S), and its metabolite in bacteria. Iyakuhin Kenkyu, 18, 12-20.